Advances in recent patent and clinical trial drug development for Alzheimer's disease.
Advances in recent patent and clinical trial drug development for Alzheimer's disease.
复制标题
DOI：
10.4155/ppa.14.22
复制
发表时间：
2014-07
影响因子：
1.3
通讯作者：
Xie XQ
中科院分区：
文献类型：
--
作者：
Liu H;Wang L;Su W;Xie XQ
阿尔茨海默病（AD）是一种进行性神经退行性疾病，涉及大量基因、蛋白质及其复杂的相互作用。目前，没有有效的治疗药物可以阻止或逆转这种疾病的进展，这可能是由于其多基因性质。 AD 复杂的病理生理学仍未得到解决。尽管推测β淀粉样蛋白级联和过度磷酸化的tau蛋白可能主要参与其中，但也涉及其他机制，例如氧化应激、中枢胆碱能神经递质缺乏、线粒体功能障碍和炎症。本次综述的主要重点是根据其主要作用机制记录目前处于临床试验中的治疗药物和正在开发的专利候选化合物。它还讨论了最近对关键靶点的理解与治疗 AD 的潜在治疗药物的开发之间的关系。
Alzheimer’s disease (AD) is a progressive neurodegenerative disease, involving a large number of genes, proteins and their complex interactions. Currently, no effective therapeutic agents are available to either stop or reverse the progression of this disease, likely due to its polygenic nature. The complicated pathophysiology of AD remains unresolved. Although it has been hypothesized that the amyloid β cascade and the hyper-phosphorylated tau protein may be primarily involved, other mechanisms, such as oxidative stress, deficiency of central cholinergic neurotransmitter, mitochondrial dysfunction and inflammation have also been implicated. The main focus of this review is to document current therapeutic agents in clinical trials and patented candidate compounds under development based on their main mechanisms of action. It also discusses the relationship between the recent understanding of key targets and the development of potential therapeutic agents for the treatment of AD.